Intellect Embraces Wide-Ranging Approach to Fighting Brain Diseases

Intellect Neurosciences’ CEO talks about the day-to-day struggles of a small biotech trying to develop drugs for neurodegenerative diseases. Among its successes is an out-licensing deal with ViroPharma to develop Intellect’s OX1 for Friedreich’s Ataxia. Similar to metal-binding compounds being developed by Prana and Varinel, OX1 is a potent anti-oxidant with purported ability to bind iron and minimize free radical damage. Given its mechanism of action, OX1 may be therapeutically relevant for ALS.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail